P53 and Prognosis Cell Volume 120, Issue 1, Pages 7-10 (January 2005)

Slides:



Advertisements
Similar presentations
SOD1 Integrates Signals from Oxygen and Glucose to Repress Respiration Amit R. Reddi, Valeria C. Culotta Cell Volume 152, Issue 1, Pages (January.
Advertisements

Individualized Medicine from Prewomb to Tomb Eric J. Topol Cell Volume 157, Issue 1, Pages (March 2014) DOI: /j.cell Copyright.
What We Talk About When We Talk About Fat Evan D. Rosen, Bruce M. Spiegelman Cell Volume 156, Issue 1, Pages (January 2014) DOI: /j.cell
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity Michael S. Rooney, Sachet A. Shukla, Catherine J. Wu, Gad Getz,
Transcriptional Control of Gene Expression by MicroRNAs Basel Khraiwesh, M. Asif Arif, Gotelinde I. Seumel, Stephan Ossowski, Detlef Weigel, Ralf Reski,
Xenobiotics Shape the Physiology and Gene Expression of the Active Human Gut Microbiome Corinne Ferrier Maurice, Henry Joseph Haiser, Peter James Turnbaugh.
Cancer Metabolism Cell Volume 148, Issue 3, (February 2012) DOI: /j.cell Copyright © 2012 Terms and Conditions Terms and Conditions.
The Good Fat Cell Volume 147, Issue 7, (December 2011) DOI: /j.cell Copyright © 2011 Terms and Conditions Terms and Conditions.
DNA Entry into and Exit out of the Cohesin Ring by an Interlocking Gate Mechanism Yasuto Murayama, Frank Uhlmann Cell Volume 163, Issue 7, Pages
c-Kit as a Novel Potential Therapeutic Target in Colorectal Cancer
Mutant p53 gain of function: The NF-Y connection
A Time to Divide: Does the Circadian Clock Control Cell Cycle?
Approaching TERRA Firma: Genomic Functions of Telomeric Noncoding RNA
Inactivation of Stat3 in tumor cells
Cell signaling and cancer
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Volume 2, Issue 3, Pages (September 2002)
Epithelial-Mesenchymal Transitions
Wild-Type p53: Tumors Can't Stand It
Regulating Cancer Stem Cells the miR Way
William J. Blake, James J. Collins  Cell 
In This Issue Cell Volume 158, Issue 5, (August 2014)
Volume 131, Issue 1, Pages (October 2007)
Peter J. Nelson, Thomas O. Daniel  Kidney International 
A Nuclear Strike against Listeria— The Evolving Life of LXR
TRRAP and the Maintenance of Stemness in Gliomas
p53 and Metabolism: The GAMT Connection
Apoptosis-targeted therapies for cancer
MicroRNAs and Parallel Stem Cell Lives
The Importance of Timing
KLF4 Initiates Acinar Cell Reprogramming and Is Essential for the Early Stages of Pancreatic Carcinogenesis  Ravikanth Maddipati, Jonathan P. Katz  Cancer.
A Dead End for MicroRNAs
Volume 152, Issue 1, (January 2013)
Lung Cancer: A Wily Genetic Opponent
Multiplying Messages LRRK beneath Parkinson Disease
The Many Faces of PPARγ Cell
Volume 130, Issue 6, (September 2007)
Tumor Suppression by p53: Fall of the Triumvirate?
Current Compensation in Neuronal Homeostasis
Lung Cancer Resets the Liver’s Metabolic Clock
Proteins Kinases: Chromatin-Associated Enzymes?
p38δ and PKD1: Kinase Switches for Insulin Secretion
The Role of PML in Tumor Suppression
Blinded by the Light: The Growing Complexity of p53
Volume 143, Issue 6, (December 2010)
Apoptosis-targeted therapies for cancer
Regulatory RNAs in Bacteria
Mark S. Sundrud, Anjana Rao  Immunity 
Endothelial Cells Form a Phalanx to Block Tumor Metastasis
Volume 14, Issue 4, Pages (October 2008)
Lan-Hsin Wang, Nicholas E. Baker  Developmental Cell 
The Long Tail of mRNA Regulation
Long Noncoding RNAs and Hepatocellular Carcinoma
The Plasticity of Aging: Insights from Long-Lived Mutants
p53 Cell Volume 110, Issue 1, Pages 9-12 (July 2002)
372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency    Molecular.
Cytokine Signaling Modules in Inflammatory Responses
Under Pressure: Stromal Fibroblasts Change Their Ways
To Infinium, and Beyond! Cancer Cell
GWAS Meets TCGA to Illuminate Mechanisms of Cancer Predisposition
Volume 163, Issue 4, (November 2015)
Volume 163, Issue 2, (October 2015)
Discovery of a Secreted Tumor Suppressor Provides a Promising Therapeutic Strategy for Follicular Lymphoma  Marc R. Mansour, A. Thomas Look  Cancer Cell 
Ewing's sarcoma: General insights from a rare model
Volume 134, Issue 6, (September 2008)
Pharmacological Rescue of p53 in Cancer Therapy: Widening the Sensitive Tumor Spectrum by Targeting MDMX  Jean-Christophe Marine  Cancer Cell  Volume.
In This Issue Cell Volume 145, Issue 3, (April 2011)
Volume 148, Issue 1, (January 2012)
Targeting Protein Stability with a Small Molecule
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Presentation transcript:

P53 and Prognosis Cell Volume 120, Issue 1, Pages 7-10 (January 2005) Karen H. Vousden, Carol Prives  Cell  Volume 120, Issue 1, Pages 7-10 (January 2005) DOI: 10.1016/j.cell.2004.12.027

Figure 1 More Than One Way to Block p53 While loss of p53 activity appears to be essential for malignant progression, there are several routes through which this can be achieved. Each of these different mechanisms blocks p53 activity, but their downstream effects may be profoundly different. Examples shown here are the expression of mutant forms of p53 or expression of excess Mdm2. Both may inhibit the regulation of target genes involved in tumor suppression by either p53 or p53 homologs p63 and p73. However, mutant p53 and Mdm2 each have additional unique targets, and perturbations in these may result in important differences in the phenotype of the resulting tumor. Cell 2005 120, 7-10DOI: (10.1016/j.cell.2004.12.027)